Drug Trial Radar · NCT01477606
Protocol in Acute Myeloid Leukemia With FLT3-ITD
Last checked: Nov 19, 2026Latest source record: Jun 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
451
Actual
Start
May 2012
Primary completion
Feb 26, 2020
Study completion Feb 26, 2020
Sponsor
- Lead sponsor
- University of UlmAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis Pharmaceuticals
- First posted
- Nov 22, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, single-arm, open-label, multi-center study in adult patients with Acute Myeloid Leukemia (AML) and FLT3-ITD as defined in inclusion/exclusion criteria. The primary efficacy object is to evaluate the impact of midostaurin given in combination with intensive induction, consolidation including allogeneic hematopoietic stem cell transplantation and single agent maintenance therapy on event-free survival (EFS) in adult patients with AML exhibiting a FLT3-ITD. Sample size: 440 patients The treatment duration of an individual patient is between 18 and 24 months. Duration of the study for an individual patient including treatment (induction, consolidation \[chemotherapy or allogeneic SCT\], maintenance and follow-up period: Maximum 8 years
Conditions
- Acute Myeloid Leukemia
Interventions
MidostaurinDrug
Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle. Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy. Maintenance therapy: 50 mg oral twice daily over one year.
CytarabineDrug
Induction therapy: 200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²) Consolidation therapy: Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2). Older patients (\>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2).
DaunorubicinDrug
Induction therapy: 60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free SurvivalTime frame: 8years
Locations
55 sites in 2 countries. Site status is shown where the registry gives one.
Medizinische Universität Innsbruck
Innsbruck, Austria
Krankenhaus der Barmherzigen Schwestern Linz
Linz, Austria
Krankenhaus der Elisabethinen Linz GmbH
Linz, Austria
Universitätsklinik für Innere Medizin III Salzburg
Salzburg, Austria
Hanuschkrankenhaus Wien
Vienna, Austria
Helios Klinikum Bad Saarow
Bad Saarow, Germany
Vivantes Klinikum Neukölln
Berlin, Germany
Charité Universitätsmedizin Berlin
Berlin, Germany
Marienhospital Bochum-Herne
Bochum, Germany
Medizinische Universitätsklinik Bochum
Bochum, Germany
Universitätsklinikum Bonn
Bonn, Germany
Städtisches Klinikum Braunschweig gGmbH
Braunschweig, Germany
Klinikum Bremen-Mitte gGmbH
Bremen, Germany
Klinikum Darmstadt
Darmstadt, Germany
Universitätsklinkum Düsseldorf
Düsseldorf, Germany
Kliniken Essen-Süd
Essen, Germany
Klinik für Onkologie, Gastroenterologie und Allg. Innere Medizin Esslingen
Esslingen am Neckar, Germany
Malteser Krankenhaus St. Franziskus Hospital Flensburg
Flensburg, Germany
Medizinische Universitätsklinik Freiburg
Freiburg im Breisgau, Germany
MVZ Osthessen
Fulda, Germany
Klinik der Justus-Liebig-Universität Gießen
Giessen, Germany
Wilhelm-Anton-Hospital gGmbH Goch
Goch, Germany
Universitätsmedizin Göttingen
Göttingen, Germany
Universitätsklinikum Eppendorf
Hamburg, Germany
Asklepios Klinik Altona
Hamburg, Germany
Evangelisches Krankenhaus Hamm
Hamm, Germany
Klinikum Region Hannover GmbH
Hanover, Germany
Medizinische Hochschule Hannover
Hanover, Germany
SLK Kliniken Heilbronn GmbH
Heilbronn, Germany
Universitätskliniken des Saarlandes
Homburg/Saar, Germany
Städtisches Klinikum Karlsruhe
Karlsruhe, Germany
Städtisches Krankenhaus Kiel GmbH
Kiel, Germany
Caritas Krankenhaus Lebach
Lebach, Germany
Klinikum Lippe-Lemgo
Lemgo, Germany
Märkische Kliniken GmbH Lüdenscheid
Lüdenscheid, Germany
Universitätsklinikum der Otto-von-Guericke Universität Magdeburg
Magdeburg, Germany
Universitätsklinikum der Johannes Gutenberg-Universität Mainz
Mainz, Germany
Johannes Wesling Klinikum Minden
Minden, Germany
Klinikum Schwabing
München, Germany
Klinikum rechts der Isar der TU München
München, Germany
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.